Team:NEFU China/Biosafety

From 2014.igem.org

Revision as of 03:20, 18 October 2014 by LiTong (Talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Biosafety

Overview

All of NEFU_China members completed safety training before the start of our project. The programs about safety training can be found here: http://dept.nefu.edu.cn/life/list/?227_1.html.(Chinese version). The Laboratory Biosafety Manual published by WHO has provided practical guidance for us. We work in a BSL1 lab equipped well to meet the safety criteria.

Q&A Section

  • Q1. Please describe the chassis orgamisms you will be using in your project.
  • Species name

    Risk Group

    Risk Group Source

    Disease risk to humans?

    1

    Synechococcus elongates PCC7942

    1

    http://www.atcc.org/Products/All/33912.aspx

    No

    2

    Bacillus subtilis

    1

    It’s widely spread in the environment.   And it is used in various areas and beneficial to human.

    No

    3

    E.coli (DH5α)

    1

    www.absa.org/riskgroups/bacteriasearch.php?genus=Escherichia

    No

    4

    E.coli (Rosetta pLysS)

    1

    www.absa.org/riskgroups/bacteriasearch.php?genus=Escherichia

    No

  • Q2. List and describe all new parts you will be using in your project.
  • Part name

    Natural function of part

    How did you acquire it?

    How will you use it?

    1

    BBa_K1509000

    Coding SmtB

    Using PCR to isolate it from

    Synechococcus elongates

    PCC7942

    Bind and regulate

    smtO/P

    2

    BBa_K1509001

    A regulator which is affected by

    SmtB protein

    Using PCR to isolate it from

    Synechococcus elongates

    PCC7942

    Detect the heavy

    metal ions with part1

    3

    BBa_K1509002

    Mainly responsible for

    flocculent activity

    Using PCR to isolate it from Bacillus   subtilis

    Flocculate bacteria

    to collect nanocrystals

    4

    BBa_K1509003

    A strong

    constitutive promoter

    Synthesized by BGI Tech

    regulate CDS7

    gene expression

  • Q3. Risks to the safety and health of team members or others working in the lab?
  • We worked in a BSL1 lab and all of us had received the safety training. We have worked out an emergency package.
  • Q4. What safety training have you received?
  • In July, we completed Laboratory Biosafety Manual, Chemical/Fire/Electrical safety trainings before the start of our wet lab work. You can get more information here:http://dept.nefu.edu.cn/life/list/?227_1.html(Chinese version) If you have any questions, please contact us.
  • Q5. Risks to the security through malicious misuse by individuals, groups, or countries?
  • The biological materials we used have no menace and we have effective measures to prevent someone from misusing.
  • Q6. If your project moved from a small-scale lab study to become widely used as a commercial/industrial product, what new risks might arise? Also, what risks might arise if the knowledge you generate or the methods you develop became widely available?
  • Our project includes special feature to reduce this risk. The flocculation module was designed to carry our project forward to commercial/industrial product.
  • Q7. Does your country have national biosafety regulations or guidelines? If so, please provide a link to these regulations or guidelines if possible.
  • Here you can see our national biosafety regulations and guidelines: http://www.stee.agri.gov.cn/biosafety(Chinese version) If you have any questions, please contact us.